On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...
LITTLETON, Colo., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development ...
Vivos Therapeutics, Inc. ('Vivos” or the 'Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing‑related sleep disorders such as ...
Vivos Therapeutics, Inc. has announced that its VidaSleep™ oral appliance, equipped with FDA-cleared Unilateral Bite Block technology, has received approval from the Centers for Medicare & Medicaid ...
Randomized controlled clinical trial using Vivos’ DNA Oral Appliance Therapy to study the DNA’s impact on OSA versus CPAP LITTLETON, Colo., Oct. 11, 2023 (GLOBE ...
Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos System HIGHLANDS RANCH, Colo., March 30, 2021 (GLOBE NEWSWIRE) -- ...
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos” or the "Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development ...
LITTLETON, Colo., June 22, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the ...
“2025 was a pivotal year for Vivos,” said (Co-Founder, Chairman of the Board & CEO R. Kirk Huntsman), adding that the company “proved our core thesis around patient demand and preference for our Vivos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results